Remove Drug Development Remove Pharma Companies Remove Trials
article thumbnail

UK Pharma Company Scancell Selects COVID-19 Vaccine for Clinical Trials | 2020-12-21

The Pharma Data

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.

article thumbnail

Why Do Pharma Companies Outsource to CROs?

Vial

Clinical trials play a crucial role in advancing medical breakthroughs, but effective management is essential to unlock their full potential. Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. over the forecast period (2022-2030).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.

article thumbnail

Claims that AI will “revolutionise pharma R&D” are (almost entirely) hype

DrugBaron

Billions of dollars have been invested in companies promising to “revolutionise pharma R&D” through the application of artificial intelligence – but it is now clear that global pharma companies, and not just tech bro’s, are buying into the claims. And there is no doubt that there is plenty of room for improvement.

article thumbnail

#Unshackled: The evolving definition of asset-centricity

DrugBaron

Buoyed by the string of successes in early discovery delivered by this approach, attention inevitably turned to how we might leverage the same insights to improve return on capital in the rest of the long path through drug development. Examples, such as post-hoc analyses of failed trials, are today too numerous to even be notorious.

article thumbnail

Drug Repurposing: A New Life for Old Drugs

DrugBank

  The benefits of drug repurposing are clear: development times and costs are significantly reduced due to existing knowledge about the drug's properties. These include matching molecular signatures, virtual screening, and analyzing large datasets from health records and clinical trials.

Drugs 71
article thumbnail

4 ways ex vivo models offer Pharma better alternatives to animal testing

Reprocell

Pharma companies are legally required to test novel drugs in animal models before beginning human trials. And while animal testing has progressed thousands of therapeutics that we use today, it is not without its experimental and ethical downfalls.